about
Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.A rare recessive distal hereditary motor neuropathy with HSJ1 chaperone mutation.Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity.Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways.The role of B cells in the early onset of the first demyelinating event of acute optic neuritis.Expression of functional luteinizing hormone (LH) receptor and its messenger ribonucleic acid in bovine uterine veins: LH induction of cyclooxygenase and augmentation of prostaglandin production in bovine uterine veins.Staurosporine stimulates progesterone production by bovine placental cells.Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.Global map of physical interactions among differentially expressed genes in multiple sclerosis relapses and remissions.Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases.Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis.Gene expression analysis reveals functional pathways of glatiramer acetate activation.Do motor impairments detected on onset of multiple sclerosis suggest an early second attack? A prospective study.Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.Induction of cyclooxygenase and prostaglandin E2 production by the bovine pre-embryo.Prostaglandin production by the oocyte cumulus complex around the time of fertilization and the effect of prostaglandin E on the development of the early bovine embryo.Use of sperm plasmid DNA lipofection combined with REMI (restriction enzyme-mediated insertion) for production of transgenic chickens expressing eGFP (enhanced green fluorescent protein) or human follicle-stimulating hormone.Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways.Regulation of bovine cervical secretion of prostaglandins and synthesis of cyclooxygenase by oxytocinAutoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosusIntravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trialImpaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapseMicroarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosisMonocyte chemoattractant protein-1 in the aqueous humour of patients with age-related macular degenerationCharacterization of multiple sclerosis traits: nuclear receptors (NR) impaired apoptosis pathway and the role of 1-α 25-dihydroxyvitamin D3The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factorsThe role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures
P50
Q33485522-DAF2954A-58F0-4AD3-A535-1A3AE17DAFBCQ34450447-A099FF8E-6432-4933-80EA-F7ECAB4E45ADQ35847422-1478E274-2044-42AF-B5DD-41DCC5C4FB1DQ37328215-04D80F4B-3787-414A-B0C3-AE5AA37E7850Q38301931-CD8F7A30-9514-4B7D-A0E5-14B9D90B52B4Q38868240-1E1147C4-FEE7-4AD2-A372-03BCFAD8903DQ38912328-1744BBEB-832B-4876-A7EA-0347EC4D3077Q40528528-97FF260D-6E36-4F5A-9DFC-07472E2ECAFDQ40982766-86B510CE-D963-44F5-A19C-A1B9CEB0CEF6Q41576536-E09B9E7C-DEFF-47C4-A048-026C9C7142ECQ42446082-A118C0B9-6BBA-4E4F-B65B-54B9E09C7A8FQ42491587-22464CC5-0392-471A-82BE-5C5460DDB73BQ43116803-254B69A4-BA46-4138-A540-D280A427E29FQ43935224-D4F60416-076C-4820-811B-1C3194335CAAQ44185075-45F4BD9F-4769-40D7-A1F7-788F27A6F5DCQ44288054-CF033653-71D1-40F7-A75A-D336F95FF100Q45135279-87D663FA-B431-416D-91D2-676EA7957F3CQ45344153-6D1D4F19-F2D8-4D48-AE0A-02E065CA49F7Q47188693-E51D7E3D-9F7F-41E4-9C0F-9E4792BA5EB1Q48916747-91490294-FD5B-450D-AD8C-08DA43286A74Q49123518-63DB4AED-CC71-470B-BE55-C465471BCFD3Q49158746-2C00F15C-ADE4-407B-ADAE-CDBEDC5024C4Q50605426-E4D8A295-C9F9-4A34-9A43-1CB845A5C28CQ50949566-3EE11BDA-4FB0-48AD-B478-DBDBD1EB1F0AQ51626712-BABFF007-1F58-4A45-97DB-AA07D8A66726Q74004841-8715AF0E-AA2D-4633-804F-BACFD9C8DAF6Q80576940-BDE9517B-A926-4825-B8F0-9BDAED941CA5Q80847140-3AE093A0-AE1D-4009-8434-FF9F86267447Q81097566-8DCE191D-7128-4EFA-BE80-9C4A01AE6C08Q82537311-CFC2BE21-1295-4044-9003-C896E101A09CQ82974956-4BDD906E-FA33-4EC7-83C4-84FF936721DAQ84552037-5FD64DBD-64B4-48CD-B54F-75B50896305EQ84868734-9F00B4AD-F52B-47A3-ADBB-02FF6560DEA9Q85200100-29C8A9B0-DF4B-4895-8BF9-77E7899CD052
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Gurevich
@ast
Michael Gurevich
@en
Michael Gurevich
@es
Michael Gurevich
@sl
type
label
Michael Gurevich
@ast
Michael Gurevich
@en
Michael Gurevich
@es
Michael Gurevich
@sl
prefLabel
Michael Gurevich
@ast
Michael Gurevich
@en
Michael Gurevich
@es
Michael Gurevich
@sl
P106
P21
P31
P496
0000-0003-1529-4876